Wall Street analyst estimates for Elutia Inc (ELUT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.15 | ||
| 2026-08-13 | $-0.17 | $-0.15 | -13.3% |
| 2026-05-14 | $-0.17 | $-0.15 | -13.3% |
| 2026-03-11 | $-0.14 | $-0.14 | +0.0% |
| 2025-11-06 | $-0.01 | $-0.15 | +93.5% |
| 2025-08-14 | $-0.26 | $-0.17 | -52.9% |
| 2025-05-08 | $-0.21 | $-0.20 | -5.0% |
| 2025-03-06 | $-0.26 | $-0.25 | -4.0% |
Valuation Ratios
| P/E Ratio | 0.60 |
| Price / Book | 2.18 |
| EV / EBITDA | -1.13 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.0M | $42.9M | $42.7M | $47.4M | $23.8M | $24.7M | $24.4M | $12.3M |
| Cost of Revenue | $23.1M | $23.1M | $22.1M | $28.4M | $12.2M | $13.7M | $13.7M | $5.7M |
| Gross Profit | $15.9M | $19.8M | $20.6M | $19.0M | $11.6M | $11.1M | $10.7M | $6.6M |
| Research & Development | $2.5M | $2.4M | $6.0M | $9.3M | $7.7M | $4.4M | $3.8M | $4.2M |
| Selling, General & Admin | $21.7M | $25.8M | $28.2M | $32.5M | $33.9M | $27.2M | $31.2M | $20.8M |
| Operating Expenses | $24.2M | $28.2M | $34.2M | $42.1M | $46.8M | $41.6M | $46.4M | $25.0M |
| Operating Income | -$8.2M | -$8.4M | -$13.6M | -$23.0M | -$35.2M | -$30.5M | -$35.7M | -$18.4M |
| EBITDA | -$2.2M | -$2.7M | -$12.3M | -$15.7M | -$27.3M | -$31.9M | -$45.9M | -$13.5M |
| Interest Expense | $5.5M | $5.4M | $5.6M | $5.3M | $5.1M | $5.8M | $4.8M | -$387000 |
| Pre-tax Income | -$11.5M | -$11.9M | -$21.8M | -$24.8M | -$36.1M | -$41.2M | -$54.1M | -$15.9M |
| Income Tax | $26000 | $30000 | $26000 | $55000 | $34000 | $28000 | $7000 | $13000 |
| Net Income | -$11.6M | -$11.9M | -$21.8M | -$24.8M | -$32.9M | -$37.7M | -$53.9M | $53.4M |
| EPS | $-1.08 | $-1.12 | $-2.13 | $-2.38 | $-2.38 | $-2.07 | $-1.86 | $1.29 |
| EPS (Diluted) | $-1.08 | $-1.12 | $-2.13 | $-2.38 | $-2.38 | $-2.07 | $-1.86 | $0.87 |
| Shares Outstanding (Diluted) | $10.7M | $10.7M | $10.2M | $10.4M | $13.8M | $18.2M | $29.1M | $45.9M |
Price
| Price | $0.81 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANVS · BCAB · CALC · CELU · LTRN · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of ELUT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks